Premium
Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone
Author(s) -
Montserrat Emilio,
Alcalá Antonio,
Parody Ricardo,
Domingo Andreu,
GarcíaConde Javier,
Bueno Javier,
Ferrán Carmen,
Sanz Miguel A.,
Giralt Manuel,
Rubio Daniel,
Antón Isabel,
Estapé Jordi,
Rozman Ciril
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19851115)56:10<2369::aid-cncr2820561004>3.0.co;2-n
Subject(s) - medicine , prednisone , chlorambucil , vincristine , cyclophosphamide , gastroenterology , chronic lymphocytic leukemia , surgery , chemotherapy , leukemia
Ninety‐six patients with advanced chronic lymphocytic leukemia (CLL) (Stage C; anemia and/or thrombocytopenia of nonimmune origin) were randomized to receive either chlorambucil (CLR) (0.4 mg/kg orally, day 6) plus prednisone (PDN) (60 mg/m 2 orally, days 1–5) every 2 weeks or cyclophosphamide (600 mg/m 2 intravenously, day 6), vincristine (1 mg/m 2 intravenously, day 6), and prednisone (60 mg/m 2 orally, days 1–5) (COP) each month for 5 months. Complete remission (CR) was defined as the total disappearance of signs and symptoms related to the disease. Partial remission (PR) was considered to be achieved when, after treatment, the clinical stage changed to a less advanced one. Thirty (59%) responses (8% CR) with CLR plus PDN and 14 (31%, 2% CR) with COP were observed ( P < 0.01). The survival was not significantly different for the two groups. Patients previously treated had a lower number of responses (11/35, 31%) than those with no previous treatment (33/61, 54%) ( P < 0.05). Patients who attained a CR or a good PR had longer survivals (median not reached) than those with a poor PR (median, 25.2 months) or those who did not respond to treatment (median, 11.5 months) ( P <0.005).